BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21847521)

  • 21. [Pulmonary and lymph node metastases of renal cell carcinoma which completely responded to oral administration of UFT--a case report].
    Hoshi K; Kanbara T; Kawasaki Y; Ikeda Y; Namima T; Ohnuma T
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1315-7. PubMed ID: 17687222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
    Donskov F; von der Maase H; Henriksson R; Stiemer U; Wersäll P; Nellemann H; Hellstrand K; Engman K; Naredi P
    Ann Oncol; 2002 Mar; 13(3):441-9. PubMed ID: 11996477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.
    Hanzly M; Aboumohamed A; Yarlagadda N; Creighton T; Digiorgio L; Fredrick A; Rao G; Mehedint D; George S; Attwood K; Kauffman E; Narashima D; Khushalani NI; Pili R; Schwaab T
    Urology; 2014 May; 83(5):1129-34. PubMed ID: 24767525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma.
    Takezawa Y; Izumi K; Shimura Y; Aerken M; Natsagdorji A; Iijima M; Shigehara K; Nohara T; Narimoto K; Kadono Y; Kitagawa Y; Konaka H; Mizokami A
    Anticancer Res; 2016 Sep; 36(9):4961-4. PubMed ID: 27630356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
    Huland E; Heinzer H; Huland H
    Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of renal cell carcinoma with multiple lung metastases refractory to interferon-alpha showing complete remission by interleukin-2 monotherapy.
    Hayashi T; Miyagawa Y; Tsujimura A; Nonomura N; Minami M; Okuyama A
    Int J Urol; 2006 Jun; 13(6):805-8. PubMed ID: 16834666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.
    Birkhäuser FD; Pantuck AJ; Rampersaud EN; Wang X; Kroeger N; Pouliot F; Zomorodian N; Riss J; Li G; Kabbinavar FF; Belldegrun AS
    Cancer J; 2013; 19(3):189-96. PubMed ID: 23708063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.
    Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A
    Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Regional immunotherapy of metastatic renal cell carcinoma].
    Heinzer H; Huland E; Huland H
    Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
    Wang C; Takeda K; Shiba M; Takayama H; Munakata S
    Hinyokika Kiyo; 2016 Aug; 62(8):407-10. PubMed ID: 27624106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy in the management of metastatic renal carcinoma].
    Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
    Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
    Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
    Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
    Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
    Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
    O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
    Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study.
    Akaza H; Tsukamoto T; Onishi T; Miki T; Kinouchi T; Naito S
    Int J Clin Oncol; 2006 Dec; 11(6):434-40. PubMed ID: 17180511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma.
    Nakamoto T; Kasaoka Y; Mitani S; Usui T
    Int J Urol; 1997 Jul; 4(4):343-8. PubMed ID: 9256321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.